On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.
On behalf of OncoSec, I want to thank our shareholders for their ongoing support of our mission to develop novel intratumoral immunotherapies to treat cancer. To date, the company has never been stronger in terms of our ImmunoPulse™ technology, advanced clinical pipeline, and collaborations with academic and industry institutions.
Being cutting-edge by introducing new tech advances is great, but it’s not the only way to go in entrepreneurship. Just ask the 34-year-old Punit Dhillon.
Punit Dhillon launched OncoSec Medical in 2011, leveraging “dead technology” to develop innovative medical treatments that harness the body’s immune system to detect and fight cancer. The revolutionary breakthrough has given hope to cancer patients and helped the company to grow from $20 to $100 million in less than 4 years. In this Q&A, I talked with Punit about his innovation and entrepreneurship in general.
This Tuesday, the OncoSec team will play host to some of the most brilliant minds in immuno-oncology, with our highly anticipated symposium, “An Introspective on Immunotherapy: A Symposium on Intratumoral Therapy.” The event promises to be a notable high point during the week of J.P. Morgan’s annual healthcare conference, a week that has historically attracted the “who’s who” of the healthcare sector.
Last week, sunny San Diego was the site of a big event (no, I don’t mean, Comic Con): the 2014 DNA Vaccine Conference hosted by the International Society of DNA Vaccines (ISDV). I thought I’d take the opportunity to describe some of the “best of conference,” as seen through the completely biased eyes of OncoSec’s CMO and what it means for our mission of furthering intratumoral immunotherapy.
Tumors deploy multiple parallel mechanisms that synergize – meaning that they work together to get more bang for their buck. In this way, tumors are able to subvert the immune response and protect themselves from being eradicated by the immune system. Thus, we need to similarly deploy multiple parallel synergistic mechanisms to re-program the immune response – to re-hijack it from tumors.
It is very rare that you find a patient with a tumor that has a dominant immune checkpoint – where you can simply reverse that one mechanism and see an effect. To put it frankly, we need to move towards combination approaches in immunotherapy.
This past month, OncoSec’s Chief Medical Officer, Dr. Robert Pierce, participated in the 6th Annual Melanoma Research Alliance Scientific Retreat The conference seeks to advance the field of melanoma research, by providing an interactive forum that facilitates data sharing and discussion among key field leaders. This is accomplished through guest participation in a series of collaborative and thought-provoking activities, including panel discussions and notable speaker presentations.
We’ve had a busy year at OncoSec. From our ongoing clinical trials to the formation of our melanoma board, research agreement with Old Dominion University and in between, the last year has moved us deeper into cancer research and engaging with patient communities. As we have only a matter of days left in 2013, we would like to look back at this year in review. Here is a selection of some of our activities this year:
The holiday season around Christmas is a time to spend with family and loved ones. It’s a part of the year where many people set aside their differences and celebrate each other and their lives. Christmas can be a difficult time for cancer patients, along with many survivors: they can be stuck in the hospital, under quarantine, away from their loved ones, or bending under the weight of harsh side effect management. We would like to take a moment to show our appreciation for cancer advocates and survivors who have brought joy and laughter to those who have suffered from cancer: